Target intelligence / Profile preview

Subthalamic nucleus (STN)

Target
STN
Molecular classification
Other
01

Overview

The subthalamic nucleus (STN) is a small lens-shaped collection of neurons located ventral to the thalamus, dorsal to substantia nigra, medial to internal capsule—functionally part of the basal ganglia system. It consists mainly of excitatory glutamatergic neurons projecting primarily to other core elements within basal ganglia such as internal globus pallidus. The STN receives inhibitory GABAergic input from external globus pallidus as well as excitatory cortical input. It plays an essential role in regulating voluntary motor control by participating in both direct and indirect pathways that modulate movement initiation and suppression. Dysfunction or degeneration involving this region contributes significantly to diseases like Parkinson's; accordingly, it serves as one major neurosurgical target for deep brain stimulation aimed at alleviating refractory motor symptoms.

Other names
Nucleus of LuysCorpus of LuysBody of ForelBody of LuysNucleus subthalamicus (Latin)Corpus Luysii (Latin)Corpus hypothalamicum (Latin)Corpus subthalamicum (Latin)
02

Mechanism of action

For interventions like deep brain stimulation: - Modulation/disruption of abnormal neuronal firing patterns within the STN to restore more physiological output from basal ganglia circuits. - Reduction in excessive excitatory drive to downstream nuclei that contribute to motor symptoms in Parkinson’s disease. Pharmacologically: - Indirect modulation through dopaminergic pathways affecting upstream or downstream components.

03

Biological functions

Motor control/modulationSuppression of unwanted movementsIntegration and accuracy of body movement
04

Disease associations

Neurodegenerative disease (notably Parkinson’s disease, Huntington’s disease)
05

Safety considerations

Risk of hemorrhage or infection from surgical implantation.Potential neuropsychiatric side effects including mood changes, impulsivity, cognitive disturbances.Dyskinesias or worsening speech/balance depending on electrode placement and settings.No notable safety concerns exist regarding pharmacological agents acting directly on this structure since none are clinically available.
06

Interacting drugs

Dopaminergic drugs used in Parkinson's disease indirectly affect its activity via basal ganglia circuits.

1 more in the full profile.

07

Biomarkers

No established molecular biomarkers specific for patient selection or efficacy monitoring at the level of the STN. Clinical response and imaging-based targeting are currently used.

Beyond the preview

Go deeper on Subthalamic nucleus (STN).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Subthalamic nucleus (STN).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call